Home $2.5 million boost for cancer research and patient care

$2.5 million boost for cancer research and patient care

Icon Cancer Foundation / 31 Mar, 2026

Cancer patients in Australia are set to benefit from greater access to cutting-edge treatments, thanks to a $2.5 million gift to not-for-profit organisation, Icon Cancer Foundation (ICF) from a prominent Brisbane family.

Television personality, Charli Robinson, and race car driver, Liam Talbot, have made this generous contribution to help more patients access innovative treatments and to support research that could change the future of cancer care.

“Cancer affects so many families. We wanted to support initiatives that give patients access to new cancer therapies and strengthen the research that will shape the future of cancer care,” Mr Talbot said.

“For us, this is about giving patients more options and more hope.”

Liam Talbot and Charli Robinson present Icon Cancer Foundation with a $2.5 million donation on behalf of The Talbot Foundation, to support life-changing cancer research and clinical trials.
Left-to-right: Associate Professor Jim Coward, Dr Ian Irving, Associate Professor James Morton AM, Charli Robinson, Liam Talbot, Dr Karthik Nath

Liam Talbot and Charli Robinson present Icon Cancer Foundation with transformative donation to cancer research.
Left-to-right: Dr Jonathan Ramsay, Ross Koscharsky, Leanne Hardyman, Liam Talbot, Charli Robinson

“This donation was made possible through my father Ken Talbot. I know he would be so proud of this donation that will help save lives through these treatments and it’s so important for us to have our daughters see Ken’s legacy live on through supporting Icon.”

“Cancer affects so many families. We wanted to support initiatives that give patients access to new cancer therapies and strengthen the research that will shape the future of cancer care.”
– Liam Talbot

Expanding access to cutting-edge clinical trials

ICF work closely with Icon Cancer Centre (Icon), Australia’s largest dedicated provider of integrated cancer care.

A key part of the gift will help expand Icon’s established clinical trials program, allowing Icon to deliver even more world-first studies and greater access to new and emerging treatments.

The donation will also support the continued growth of Icon’s cellular therapy program, the largest privately operated program of its kind in Australia.

Charli Robinson says that helping patients benefit from the latest treatments was at the heart of their family’s decision.

“We know access to innovative treatments can be life changing. Knowing our gift will help patients take part in pioneering trials and access the therapies they need when it matters most is incredibly important to us,” Ms Robinson said.

“Knowing our gift will help patients take part in pioneering trials and access the therapies they need when it matters most is incredibly important to us.”
– Charli Robinson

Icon’s Global Chief Medical Officer, Dr Ian Irving, says cancer is affecting more Australians than ever before.

“As demand for treatment grows, so too does the need for greater access to innovative therapies and clinical trials,” Dr Irving said.

“This investment comes at a pivotal time in cancer research, and we are very grateful to the Talbot Foundation for this incredibly generous donation.

“We’re seeing a wave of emerging therapies that are transforming outcomes, particularly for patients with more complex or treatment-resistant cancers.

“To ensure our patients can access these breakthrough treatments as early as possible, we need the capacity to open more clinical trials – this donation helps us do that.”

Icon Group Global Chief Medical Officer, Dr Ian Irving thanks Charli Robinson and Liam Talbot for their gift to cancer research.

“To ensure our patients can access these breakthrough treatments as early as possible, we need the capacity to open more clinical trials – this donation helps us do that.”
– Dr Ian Irving, Icon Group Global Medical Officer

Future healthcare, closer to home

The Talbot Foundation donation will enable Icon to build on its existing clinical trials program, bringing more world-leading research to Queensland and expanding both the number and range of trials available to patients.

The funds will also support upgraded laboratory facilities and expand access to emerging cellular therapy treatments.

“For many patients, participating in research can mean access to new treatments that are not yet widely available,” Dr Irving said.

“Strengthening this program will help more patients receive these newer therapies locally, allowing them to stay close to home rather than travel for clinical trials.”

Liam Talbot and Charli Robinson speak with Kaye, a patient at Icon Cancer Centre Chermside who has participated in two clinical trials since being diagnosed with ovarian cancer in 2017.

Over the next few years, these projects will be delivered progressively as the new facilities are built, specialist teams are recruited and trained, and research capability expands.

More updates will follow.

Search

Quick links
Contact us
Donate